Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation.
Kumar, Sandeep; Kang, Dong-Won; Rezvan, Amir; Jo, Hanjoong.
; 97(8): 935-945, 2017 08.
Artigo em Inglês | MEDLINE | ID: mdl-28504688
Selection of DNA aptamers with two modified bases.
A Compact, High-Accuracy Cas9 with a Dinucleotide PAM for In Vivo Genome Editing.
Non-Native Conformational Isomers of the Catalytic Domain of PCSK9 Induce an Immune Response, Reduce Lipids and Increase LDL Receptor Levels.
Nutritional and Lipid Modulation of PCSK9: Effects on Cardiometabolic Risk Factors.
Fetal gender and gestational age differentially affect PCSK9 levels in intrauterine growth restriction.
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Appropriate use of PCSK9 Inhibitors in India.
[Proprotein Convertase Subtilisin/Kexin-Type 9 (PCSK9) New Opportunities of Lipid-Lowering Therapy].
Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives.
Monoclonal Antibodies for Lipid Management.